Syneron Medical Ltd. (NASDAQ:ELOS)’s share price was up 3.3% during mid-day trading on Tuesday . The company traded as high as $6.71 and last traded at $6.66, with a volume of 73,985 shares trading hands. The stock had previously closed at $6.45.

A number of equities analysts have issued reports on ELOS shares. Zacks Investment Research downgraded Syneron Medical from a “hold” rating to a “sell” rating in a research note on Wednesday, May 25th. Brean Capital reiterated a “buy” rating and set a $13.00 price target on shares of Syneron Medical in a research note on Tuesday, May 31st. Finally, Leerink Swann downgraded Syneron Medical from an “outperform” rating to a “market perform” rating and cut their price target for the company from $9.40 to $7.80 in a research note on Friday, August 5th.

The company has a 50-day moving average of $6.72 and a 200-day moving average of $7.11. The stock’s market cap is $233.87 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/syneron-medical-ltd-elos-trading-3-3-higher.html

Syneron Medical (NASDAQ:ELOS) last issued its quarterly earnings data on Thursday, August 4th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.06 by $0.03. The firm earned $75 million during the quarter, compared to the consensus estimate of $75.72 million. Syneron Medical had a negative net margin of 1.42% and a positive return on equity of 2.88%. The company’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.07 earnings per share. Equities analysts forecast that Syneron Medical Ltd. will post $0.27 earnings per share for the current year.

Institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its position in shares of Syneron Medical by 5.8% in the first quarter. Geode Capital Management LLC now owns 21,010 shares of the company’s stock valued at $152,000 after buying an additional 1,159 shares during the period. Lapides Asset Management LLC increased its position in shares of Syneron Medical by 2.3% in the second quarter. Lapides Asset Management LLC now owns 290,400 shares of the company’s stock valued at $2,233,000 after buying an additional 6,400 shares during the period. California Public Employees Retirement System increased its position in shares of Syneron Medical by 17.2% in the second quarter. California Public Employees Retirement System now owns 93,825 shares of the company’s stock valued at $722,000 after buying an additional 13,800 shares during the period. Hilton Capital Management LLC purchased a new position in shares of Syneron Medical during the first quarter valued at approximately $117,000. Finally, State Street Corp increased its position in shares of Syneron Medical by 112.1% in the second quarter. State Street Corp now owns 46,038 shares of the company’s stock valued at $354,000 after buying an additional 24,337 shares during the period. 72.44% of the stock is owned by hedge funds and other institutional investors.

Syneron Medical Company Profile

Syneron Medical Ltd. is engaged in the manufacture, research, development, marketing and sale of equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company designs, develops and markets aesthetic medical products based on its various technologies, including Electro-Optical Synergy (ELOS) technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments.

5 Day Chart for NASDAQ:ELOS

Receive News & Ratings for Syneron Medical Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneron Medical Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.